RE:RE:Newbies???Like many other shareholders, I'm still waiting for updates from the company. I haven't sold a single share. I don't agree with those low targets from some analysts. Toraymyxin has not been rejected by the FDA. The device is safe and has demonstrated beneficial treatment effects across multiple endpoints. In my opinion the primary endpoint could still be reached in a small observational study with some adjustments done to the number of columns used, timing, and targeted population. The unmet medical need is huge and about nothing else is available. I'm hoping that the FDA will give us a quick pathway toward approval with data that could be retrieved from compassionate use under the expanded access protocol. I still have to figure how this device could be dismissed if it's safe, improves patient's conditions, and can potentially be saving tens of thousands of lives every year.